- Home
- JBDI vs ELEV Comparison
JBDI vs ELEV Comparison
Compare JBDI & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBDI
- ELEV
- Stock Information
- Founded
- JBDI 1983
- ELEV 2019
- Country
- JBDI Singapore
- ELEV United States
- Employees
- JBDI N/A
- ELEV N/A
- Industry
- JBDI
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- JBDI
- ELEV Health Care
- Exchange
- JBDI Nasdaq
- ELEV Nasdaq
- Market Cap
- JBDI 19.0M
- ELEV 22.6M
- IPO Year
- JBDI 2024
- ELEV 2021
- Fundamental
- Price
- JBDI $0.95
- ELEV $0.37
- Analyst Decision
- JBDI
- ELEV Hold
- Analyst Count
- JBDI 0
- ELEV 6
- Target Price
- JBDI N/A
- ELEV $1.77
- AVG Volume (30 Days)
- JBDI 36.8K
- ELEV 1.2M
- Earning Date
- JBDI 02-15-2025
- ELEV 08-05-2025
- Dividend Yield
- JBDI N/A
- ELEV N/A
- EPS Growth
- JBDI N/A
- ELEV N/A
- EPS
- JBDI N/A
- ELEV N/A
- Revenue
- JBDI $9,017,000.00
- ELEV N/A
- Revenue This Year
- JBDI N/A
- ELEV N/A
- Revenue Next Year
- JBDI N/A
- ELEV N/A
- P/E Ratio
- JBDI N/A
- ELEV N/A
- Revenue Growth
- JBDI N/A
- ELEV N/A
- 52 Week Low
- JBDI $0.49
- ELEV $0.22
- 52 Week High
- JBDI $39.41
- ELEV $3.09
- Technical
- Relative Strength Index (RSI)
- JBDI N/A
- ELEV 45.79
- Support Level
- JBDI N/A
- ELEV $0.35
- Resistance Level
- JBDI N/A
- ELEV $0.38
- Average True Range (ATR)
- JBDI 0.00
- ELEV 0.01
- MACD
- JBDI 0.00
- ELEV -0.00
- Stochastic Oscillator
- JBDI 0.00
- ELEV 34.34
About JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.